Back
Open Access

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

Session: Advances in heart failure therapeutics
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Doctor P. Tolomeo (Glasgow, GB)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Paolo Tolomeo

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
0 follower

4 more presentations in this session

Refining definitions of severe and advanced heart failure: insight from the swedish heart failure registry to optimize trial design and improve referral to advanced therapies

Speaker: Doctor F. Guidetti (Bern, CH)

Access
Abstract
Like
Thumbnail

Association between neutrophil-to-lymphocyte ratio, exercise capacity and outcomes in patients with heart failure and reduced ejection fraction

Speaker: Doctor E. Rodenas Alesina (Toronto, CA)

Access
Abstract
Like
Thumbnail

Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase

Speaker: Professor M. Petrie (Glasgow, GB)

Access
Abstract
Like
Thumbnail

Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on patients' needs and perceptions

Speaker: Ms R. Monroe (Charlotte, US)

Access
Abstract
Like
Thumbnail

Access the full session

Advances in heart failure therapeutics

Speakers: Doctor P. Tolomeo, Doctor F. Guidetti, Doctor E. Rodenas Alesina, Professor M. Petrie, Ms R. Monroe
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources